MERLOT试验:黄斑上放射治疗对经治新生血管性AMD的24个月疗效与安全性
MERLOT随机对照试验在英国24家NHS医院纳入363例既往接受雷珠单抗治疗的新生血管性ARMD患者,按2:1随机接受黄斑上放射治疗(EMB)联合按需雷珠单抗或单用按需雷珠单抗。24个月结果显示EMB未减少注射次数,且视力下降更明显,不支持其作为慢性活动性新生血管性ARMD的辅助治疗。
要点
- EMB未减少按需雷珠单抗注射次数,两组差异仅1.0次注射且无统计学意义。
- EMB组BCVA平均下降11.2个ETDRS字母,明显劣于单药组的1.4个字母。
- EMB组微血管异常发生率为9.7%,高于单药组的1.0%,安全性总体可接受。
核心结论
- EMB虽安全性可接受,但未减少雷珠单抗注射次数且视力结局劣于单用抗VEGF,不支持其作为慢性活动性新生血管性ARMD的辅助治疗。
研究设计与样本
- MERLOT关键器械试验为随机对照试验,在英国24家NHS医院开展,2009年11月10日至2012年1月30日入组。
- 患者按2:1随机分为EMB联合按需雷珠单抗组与按需雷珠单抗单药组,按晶状体状态和血管造影病灶类型分层。
- 共363例参与者,329例(90.6%)完成24个月随访,联合组平均年龄76.5(7.4)岁,采用意向性分析。
主要发现
- BCVA平均变化EMB组为-11.2(15.7)个ETDRS字母,单药组为-1.4(10.9)个字母,差异9.8个字母(95%CI,-6.7至-12.9)。
- 微血管异常在EMB组207眼中有20眼(9.7%)发生,单药组97眼中有1眼(1.0%)发生,均位于黄斑中心凹外。
关键数值与推荐
- 共同主要结局为非劣效性界值-5个ETDRS字母下的BCVA平均变化与按需雷珠单抗注射次数。
- EMB组与单药组BCVA差异为9.8个ETDRS字母(95%CI,-6.7至-12.9),超出-5字母非劣效界值。
临床怎么用
- 对慢性活动性新生血管性ARMD,不应将EMB作为减少抗VEGF注射负担的辅助治疗。
- 与患者沟通时应说明EMB联合治疗可能带来更差的视力结局和更高的微血管异常风险。
局限性
- 研究无法对参与者和临床医生设盲,但BCVA与影像由设盲评估者分析。
- 原文未报告36个月最终访视的疗效与安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although anti-vascular endothelial growth factor (VEGF) treatment offers better outcomes than the natural history of neovascular age-related macular degeneration (ARMD), a less burdensome, less expensive, and more durable treatment is needed. OBJECTIVE: To assess the efficacy and safety of epimacular brachytherapy (EMB) for chronic, active, neovascular ARMD. DESIGN, SETTING, AND PARTICIPANTS: The Macular Epiretinal Brachytherapy vs Ranibizumab (Lucentis) Only Treatment (MERLOT) pivotal device trial was conducted at 24 National Health Service hospitals across the UK. Patients who had neovascular ARMD and received intravitreal ranibizumab were enrolled between November 10, 2009, and January 30, 2012. Eligible patients were randomized 2:1 and were stratified by lens status and angiographic lesion type to receive either EMB plus as-needed ranibizumab or as-needed ranibizumab monotherapy. Participants were followed up monthly for 24 months and then assessed at a final visit at month 36. Masking of participants and clinicians was not possible, but best-corrected visual acuity (BCVA) and imaging were analyzed by masked assessors. Analysis followed the intent-to-treat approach. INTERVENTIONS: Pars plana vitrectomy with 24 Gy EMB plus as-needed ranibizumab vs as-needed ranibizumab monotherapy. MAIN OUTCOMES AND MEASURES: Coprimary outcomes were the number of as-needed ranibizumab injections and the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA with a noninferiority margin of -5 ETDRS letters. Secondary outcomes were the percentage of participants losing fewer than 15 ETDRS letters and gaining 0 or more or 15 or more ETDRS letters and the mean change in angiographic total lesion size, choroidal neovascularization size, and foveal thickness on optical coherence tomography. RESULTS: Of 363 participants, 329 (90.6%) completed 24 months of follow-up (222 participants in the EMB group and 107 in the ranibizumab group). The mean (SD) age of the combined groups was 76.5 (7.4) years. The mean (SD) number of ranibizumab injections was 9.3 (6.7) in the EMB group and 8.3 (4.5) in the ranibizumab group, with a difference of 1.0 injection (95% CI, -0.3 to 2.3; P = .13). The mean (SD) BCVA change was -11.2 (15.7) ETDRS letters in the EMB group and -1.4 (10.9) ETDRS letters in the ranibizumab group, with a difference of 9.8 ETDRS letters (95% CI, -6.7 to -12.9). In the EMB group, 65.6% of participants (160 of 244) lost fewer than 15 ETDRS letters vs 86.6% (103 of 119) in the ranibizumab group, with a difference of 21% (95% CI, 12.4%-29.5%; P < .001). Microvascular abnormalities occurred in 20 of 207 eyes (9.7%) in the EMB group and 1 of 97 eyes (1.0%) in the ranibizumab group. These abnormalities occurred outside the foveal center, and there were no unexpected safety concerns. CONCLUSIONS AND RELEVANCE: The MERLOT trial found that despite the acceptable safety of EMB, it did not reduce the number of ranibizumab injections and was associated with worse visual acuity than anti-VEGF treatment alone; these results do not support EMB use as an adjunct treatment for chronic, active neovascular ARMD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01006538.
引用
- Jackson TL, Soare C, Petrarca C, et al. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32644148. doi:10.1001/jamaophthalmol.2020.2309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。